Relay Posts $848.6M Cash, Accelerates Breast Cancer Enrollment to Mid-2027
RLAY has more than doubled off its 52-week low of $5.95.
Summary
Relay ended Q3 with $848.6 million in cash, cash equivalents and investments, down from $910.9 million at June 30, and says that funds operations into 2029. The quarter's net loss widened to $81.7 million, or $0.37 per share, from $74.1 million a year earlier, as R&D rose to $77.1 million on trial costs and lease termination charges. The key pipeline update: Phase 3 ReDiscover-2 in second-line PI3Kα-mutated breast cancer is now expected to complete enrollment in mid-2027, roughly a year faster than recent benchmarks. Relay also hired Shannon Campbell, most recently CCO at Merus, as Head of Commercial, and disclosed a new late-preclinical mutant-selective TIE2 inhibitor program for vascular malformations. Updated zovegalisib vascular anomalies data plus a regulatory update are set for an ASH oral presentation on December 14, 2026, with a company call that day; a regulatory update confirming the Phase 3 design in first-line endocrine-sensitive breast cancer is expected by year-end 2026.
At the time of this announcement, RLAY was trading at $18.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $5.95 to $21.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.